BACKGROUND: In order to assess relationships between thyroid hormone status and findings on brain MRI, a subset of babies was recruited to a multi-centre randomised, placebo-controlled trial of levothyroxine (LT4) supplementation for babies born before 28 weeks' gestation (known as the TIPIT study, for Thyroxine supplementation In Preterm InfanTs). These infants were imaged at term-equivalence. MATERIALS AND METHODS: Forty-five TIPIT participants had brain MRI using diffusion tensor imaging (DTI) to estimate white matter development by apparent diffusion coefficient (ADC), fractional anisotropy (FA) and tractography metrics of number and length of streamlines. We made comparisons between babies with the lowest and highest plasma FT4 concentrations during the initial 4 weeks after birth. RESULTS: There were no differences in DTI metrics between babies who had received LT4 supplementation and those who had received a placebo. Among recipients of a placebo, babies in the lowest quartile of plasma-free thyroxine (FT4) concentrations had significantly higher apparent diffusion coefficient measurements in the posterior corpus callosum and streamlines that were shorter and less numerous in the right internal capsule. Among LT4-supplemented babies, those who had plasma FT4 concentrations in the highest quartile had significantly lower apparent diffusion coefficient values in the left occipital lobe, higher fractional anisotropy in the anterior corpus callosum and longer and more numerous streamlines in the anterior corpus callosum. CONCLUSION: DTI variables were not associated with allocation of placebo or thyroid supplementation. Markers of poorly organised brain microstructure were associated with low plasma FT4 concentrations after birth. The findings suggest that plasma FT4 concentrations affect brain development in very immature infants and that the effect of LT4 supplementation for immature babies with low FT4 plasma concentrations warrants further study.
RCT Entities:
BACKGROUND: In order to assess relationships between thyroid hormone status and findings on brain MRI, a subset of babies was recruited to a multi-centre randomised, placebo-controlled trial of levothyroxine (LT4) supplementation for babies born before 28 weeks' gestation (known as the TIPIT study, for Thyroxine supplementation In Preterm InfanTs). These infants were imaged at term-equivalence. MATERIALS AND METHODS: Forty-five TIPIT participants had brain MRI using diffusion tensor imaging (DTI) to estimate white matter development by apparent diffusion coefficient (ADC), fractional anisotropy (FA) and tractography metrics of number and length of streamlines. We made comparisons between babies with the lowest and highest plasma FT4 concentrations during the initial 4 weeks after birth. RESULTS: There were no differences in DTI metrics between babies who had received LT4 supplementation and those who had received a placebo. Among recipients of a placebo, babies in the lowest quartile of plasma-free thyroxine (FT4) concentrations had significantly higher apparent diffusion coefficient measurements in the posterior corpus callosum and streamlines that were shorter and less numerous in the right internal capsule. Among LT4-supplemented babies, those who had plasma FT4 concentrations in the highest quartile had significantly lower apparent diffusion coefficient values in the left occipital lobe, higher fractional anisotropy in the anterior corpus callosum and longer and more numerous streamlines in the anterior corpus callosum. CONCLUSION: DTI variables were not associated with allocation of placebo or thyroid supplementation. Markers of poorly organised brain microstructure were associated with low plasma FT4 concentrations after birth. The findings suggest that plasma FT4 concentrations affect brain development in very immature infants and that the effect of LT4 supplementation for immature babies with low FT4 plasma concentrations warrants further study.
Authors: Savannah C Partridge; Pratik Mukherjee; Jeffrey I Berman; Roland G Henry; Steven P Miller; Ying Lu; Orit A Glenn; Donna M Ferriero; A James Barkovich; Daniel B Vigneron Journal: J Magn Reson Imaging Date: 2005-10 Impact factor: 4.813
Authors: Christopher M Schoonover; Melissa M Seibel; Dawn M Jolson; Mary Jo Stack; Rounak J Rahman; Sidney A Jones; Cary N Mariash; Grant W Anderson Journal: Endocrinology Date: 2004-07-15 Impact factor: 4.736
Authors: M A Rutherford; J M Pennock; S J Counsell; E Mercuri; F M Cowan; L M Dubowitz; A D Edwards Journal: Pediatrics Date: 1998-08 Impact factor: 7.124
Authors: Jessica Rose; Erin E Butler; Lauren E Lamont; Patrick D Barnes; Scott W Atlas; David K Stevenson Journal: Dev Med Child Neurol Date: 2009-04-21 Impact factor: 5.449
Authors: Stephen Correia; Stephanie Y Lee; Thom Voorn; David F Tate; Robert H Paul; Song Zhang; Stephen P Salloway; Paul F Malloy; David H Laidlaw Journal: Neuroimage Date: 2008-05-24 Impact factor: 6.556
Authors: Vann Chau; Rollin Brant; Kenneth J Poskitt; Emily W Y Tam; Anne Synnes; Steven P Miller Journal: Pediatr Res Date: 2012-01-25 Impact factor: 3.756
Authors: Jeroen Dudink; Maarten Lequin; Carola van Pul; Jan Buijs; Nikk Conneman; Johannes van Goudoever; Paul Govaert Journal: Pediatr Radiol Date: 2007-10-02